Bio-Gene Technology (ASX:BGT) Total Liabilities: A$0.31 Mil (As of Dec. 2025)


What is Bio-Gene Technology Total Liabilities?

Bio-Gene Technology ASX:BGT Total Liabilities is A$0.31 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

Bio-Gene Technology's Total Liabilities for the quarter that ended in Dec. 2025 was A$0.31 Mil.

Bio-Gene Technology's quarterly Total Liabilities declined from Dec. 2024 (A$0.54 Mil) to Jun. 2025 (A$0.52 Mil) and declined from Jun. 2025 (A$0.52 Mil) to Dec. 2025 (A$0.31 Mil).

Bio-Gene Technology's annual Total Liabilities declined from Jun. 2023 (A$0.61 Mil) to Jun. 2024 (A$0.37 Mil) but then increased from Jun. 2024 (A$0.37 Mil) to Jun. 2025 (A$0.52 Mil).

Bio-Gene Technology Total Liabilities Historical Data

* Premium members only.

The historical data trend for Bio-Gene Technology's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Gene Technology Total Liabilities Chart

Bio-Gene Technology Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Liabilities
Get a 7-Day Free Trial 0.76 1.04 0.61 0.37 0.52

Bio-Gene Technology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.60 0.37 0.54 0.52 0.31

Bio-Gene Technology Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Bio-Gene Technology's Total Liabilities for the fiscal year that ended in Jun. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.51+(0+1.2143064331838E-17
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.013+0)
=0.52

Total Liabilities=Total Assets (A: Jun. 2025 )-Total Equity (A: Jun. 2025 )
=2.15-1.627
=0.52

Bio-Gene Technology's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.305+(0+0.003
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.31

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=1.474-1.167
=0.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of A$0.31 Mil mean?
Bio-Gene Technology (ASX:BGT) has a Total Liabilities of A$0.31 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Bio-Gene Technology and its competitors.
Is Bio-Gene Technology's Total Liabilities too high?
Bio-Gene Technology's current Total Liabilities is A$0.31 Mil.
How does Bio-Gene Technology's Total Liabilities compare to VRTX and REGN?
Bio-Gene Technology's Total Liabilities of A$0.31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Bio-Gene Technology and its competitors. Bio-Gene Technology's current Total Liabilities is A$0.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Gene Technology stock overvalued right now?
Bio-Gene Technology (ASX:BGT) has a current Total Liabilities of A$0.31 Mil. The current Total Liabilities is A$0.31 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Bio-Gene Technology (ASX:BGT), the current Total Liabilities is A$0.31 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio-Gene Technology Business Description

Address 400 Collins Street, Level 6, Melbourne, VIC, AUS, 3000
Bio-Gene Technology Ltd is an Australian company developing novel bio-insecticides to address the challenges of insecticide resistance and toxicity. Its products are based on a naturally occurring class of compounds to overcome resistance to control pests with minimal impact on human health and the environment. Bio-Gene's products have multiple applications across public health, crop protection, grain storage, and consumer use. The company operates in one business segment, being the conduct of research and development activities in the discovery of novel insecticides.